Am J Transplant, Volume 18, Suppl 3 Archives - Page 18 of 211 - ATC Abstracts

2018 American Transplant Congress
Clinical Application of Mesenchymal Stromal Cells with a Simplified Protocol for ABO Incompatible Liver Transplantation in Severe Hepatic Failure Patients
Y. Zhang,^1,2 J. Zheng,^1,2 J. Cai,^1,2 J. Zhang,^1,2 K. Zeng,^1,2 J. Yao,^1,2 Y. Yang.^1,2
¹Department of Hepatic Surgery and Liver Transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute, Sun Yat-sen University, Guangzhou, Guangdong, China; ²Guangdong Key Laboratory of Liver Disease Research, Key Laboratory of Liver Disease Biotherapy and Translational Medicine of Guangdong Higher Education Institutes, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, .
Objective The purpose of this study was to test the safety and efficacy of mesenchymal stromal cells (MSCs) treatment with a simplified protocol for ABO…
2018 American Transplant Congress
Increased Pre-Transplant Rejection-Risk Measured with Allospecific T-Cells Predicts Delayed Immunosuppression Minimization in Children with Intestine Transplantation.
K. Soltys, C. Ashokkumar, G. Mazariegos, G. Bond, M. Ningappa, A. Khanna, A. Ganoza, Q. Sun, R. Sindhi.
Pediatric Abdominal Transplant, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA.
BACKGROUND: Allospecific CD154+T-cytotoxic memory cells (CD154+TcM) are used clinically to predict acute cellular rejection (ACR) after intestine transplantation (ITx) in children <21 years old within…
2018 American Transplant Congress
Type I NKT Cells Augment Humoral and Cellular Alloimmunity in Response to Hepatocyte Transplantation
S. Elzein, J. Zimmerer, B. Ringwald, C. Avila, G. Bumgardner.
Surgery, The Ohio State University Wexner Medical Center, Columbus, OH.
Hepatocyte transplantation (HcTx) is a potential therapeutic modality for patients with liver disease. Despite examples of antigen acceptance in the liver, allogeneic HcTx into patients…
2018 American Transplant Congress
Outcomes of DCD Renal Transplantation from Donors with Acute Kidney Injury
E. Grodstein, J. Yang, V. Nair, L. Teperman.
Northwell Health, Manhasset, NY.
BackgroundDeceased donor kidneys with acute kidney injury (AKI) are a viable source of organs, yet are frequently discarded. Outcomes of deceased donor renal transplantation (DDRT)…
2018 American Transplant Congress
Is Age a Potential Barrier to Pursuing Living Donor Kidney Transplant (LDKT)?
A. Raissi, N. Edwards, Y. Liao, D. Belenko, N. Singh, M. Khalid, D. Toews, I. Mucsi.
Multi-Organ Transplant Program, Department of Surgery, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
BackgroundThe incidence of end stage kidney disease (ESKD) among older adults (65+) is increasing. Living Donor Kidney Transplant (LDKT) may provide improved outcome even for…
2018 American Transplant Congress
A Medical Decision Analysis for the Use of Donation after Cardiac Death Donors for Simultaneous Liver-Kidney Transplant
A. Miller, K. Tennankore, B. Kiberd.
Division of Nephrology, Department of Medicine, Dalhousie University, Halifax, NS, Canada.
For patients on the simultaneous liver-kidney transplant (SLKT) waitlist, acceptance of donation after cardiac death (DCD) organs may facilitate earlier transplantation thereby reducing waitlist mortality,…
2018 American Transplant Congress
Prolonged Graft Survival in Old Recipients is Abrogated by Immunosuppressive Treatment with CTLA4-Ig
T. Heinbokel,¹ M. Quante,^1,2 K. Edtinger,¹ K. Minami,¹ Y. Nian,¹ A. Lau,¹ A. Elkhal,¹ S. Tullius.¹
¹Transplant Surgery Research Lab, Brigham and Women's Hospital, Boston, MA; ²Department of General, Visceral and Transplant Surgery, Tuebingen Unversity Hospital, Tuebingen, Germany.
Although they represent a rapidly growing population, elderly organ transplant recipients are underrepresented in clinical trials. Age-specific aspects of established immunosuppressants are therefore poorly understood.Here,…
2018 American Transplant Congress
Dependency on CD4 T Cells, Foreign Protein, and CD22 for Generation of Antibody Response to Non-Self Blood Group A-Antigen in a Mouse Model
I. Adam, B. Motyka, K. Tao, L. West.
Alberta Transplant Institute, Canadian National Transplant Research Program, University of Alberta, Edmonton, AB, Canada.
Background: ABO-incompatible heart transplantation (ABOi-HTx) is safe during infancy and allows increased donor access. B cell tolerance develops to donor A/B-antigens (Ag) after ABOi HTx…
2018 American Transplant Congress
SIRT1-Ikaros Axis Promotes Macrophage M2 Polarization and Protects Liver Graft from Ischemia-Reperfusion Injury
K. Nakamura,¹ S. Kageyama,¹ X. Li,² A. Aziz,¹ R. Sosa,³ E. Reed,³ F. Kaldas,¹ R. Busuttil,¹ J. Kupiec-Weglinski.¹
¹Surgery, Liver Transplant, UCLA, Los Angeles, CA; ²NIEHS, Durham, NC; ³Pathology, UCLA, Los Angeles, CA.
Although pre-clinical studies have reported the efficacy of Sirtuin 1 (SIRT1) to protect livers from ischemia-reperfusion injury, its clinical relevance in liver transplantation (LT) has…
2018 American Transplant Congress
Inflammation in Scarred Areas (I-IFTA) is a Reflection of Parenchymal Injury (Response to Wounding) Not T Cell-Mediated Rejection
P. Halloran, J. Chang, K. Famulski.
Medicine, University of Alberta, Edmonton, AB, Canada.
Inflammation in fibrotic renal parenchyma (i-IFTA) is associated with decreased graft survival but by Banff rules is not diagnostic for rejection. Some researchers believe that…